ABL1 and melanoma: Consistent with these data, expression of constitutively active forms of ABL1/2 (P242E/P249E; PP)23,26 into melanoma cells lacking highly active ABL1/2 and harboring BRAF-V600E (WM164; gain-of-function experiment)16 is sufficient to induce BRAFi resistance (Fig. 2h and Supplementary Fig. 2h).